Archive · 26 Jan 2026
Syngene Focuses on Chemistry for Growth Amid Revenue Decline
Syngene International is a company that helps with drug discovery and manufacturing.
Recently, they had a drop in their quarterly revenue due to some inventory and client issues.
However, they are focusing more on chemistry research to grow in the future.
Their CEO, Peter Bains, says that chemistry, along with biology and clinical research, will be key to their growth.
They also expect to work more on new types of medicines like antibody-drug conjugates.
Even though their profit decreased this quarter, they are optimistic about the long-term outlook.
Syngene International is focusing on chemistry-led research for future growth.
Q3 FY26 revenue was ₹617 crore, impacted by inventory correction and client-specific issues.
The company expects a 3-5% decline in full-year revenue.
Research services, particularly chemistry, biology, and translational clinical research, are key growth areas.
Syngene is well-positioned to capitalize on emerging modalities like antibody-drug conjugates and PROTACs.
- Who
- Syngene International, led by MD & CEO Peter Bains
- What
- Shift in focus to chemistry-led research for future growth
- When
- Q3 FY26 (January 26, 2026)
- Where
- Global, with a focus on diversified research and manufacturing services
- Why
- To drive long-term growth and position as a partner rather than a project vendor
- Company
- Syngene International
- Q3 FY26 Revenue
- ₹617 crore
- Expected Annual Revenue Decline
- 3-5%
- Q3 PAT (excluding one-time impact)
- ₹73 crore
- Key Growth Areas
- Chemistry, Biology, Translational Clinical Research
- Emerging Modalities
- Antibody-drug conjugates, peptides, PROTACs, oligonucleotides